Literature DB >> 34902271

Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.

Mohammad H Alshaer1,2, Sylvain Goutelle3,4,5, Barbara A Santevecchi2, Bethany R Shoulders2, Veena Venugopalan2, Kartikeya Cherabuddi6, Jiajun Liu7, Patrick J Kiel8, Jason A Roberts9,10,11,12, Fekade Bruck Sime9,13, Marc H Scheetz14,15,16,17, Michael N Neely18, Charles A Peloquin1,2.   

Abstract

Cefepime is the second most common cephalosporin used in U.S. hospitals. We aim to develop and validate a cefepime population pharmacokinetic (PK) model and integrate it into a precision dosing tool for implementation. Two data sets (680 patients) were used to build the cefepime PK model in Pmetrics, and three data sets (34 patients) were used for the validation. A separate application data set (115 patients) was used for the implementation and validation of a precision dosing tool. The model support points and covariates were used to generate the optimal initial dose (OID). Cefepime PK was described by a two-compartment model including weight and creatinine clearance (CrCl) as covariates. The median rate of elimination was 0.30 h-1 (adults) and 0.96 h-1 (children), the central volume of distribution was 13.85 L, and the rate of transfer from the central to the peripheral compartments was 1.22 h-1 and from the peripheral to the central compartments was 1.38 h-1. After integration in BestDose, the observed versus predicted cefepime concentration fit using the application data set was excellent (R2 > 0.98), and the median difference between what was observed and what BestDose predicted on a second occasion was 4%. For the OID, cefepime at a 0.5- to 1-g 4-h infusion every 8 to 24 h (q8 to 24 h) with a CrCl of <70 mL/min was needed to achieve a target range of free trough:MIC 1 to 4 at a MIC of 8 mg/L, while continuous infusion was needed for higher CrCl and weight values. In conclusion, we developed and validated a cefepime model for clinical application. The model was integrated in a precision dosing tool for implementation, and the median concentration prediction bias was 4%. The OID algorithm was provided.

Entities:  

Keywords:  cefepime; pharmacokinetics; precision dosing

Mesh:

Substances:

Year:  2021        PMID: 34902271      PMCID: PMC8846452          DOI: 10.1128/AAC.02046-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  32 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children.

Authors:  M D Reed; T S Yamashita; C K Knupp; J M Veazey; J L Blumer
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.

Authors:  Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

4.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

5.  An exploratory analysis of the ability of a cefepime trough concentration greater than 22 mg/L to predict neurotoxicity.

Authors:  Nathaniel J Rhodes; Joseph L Kuti; David P Nicolau; Michael N Neely; Anthony M Nicasio; Marc H Scheetz
Journal:  J Infect Chemother       Date:  2015-12-17       Impact factor: 2.211

6.  Adequacy of high-dose cefepime regimen in febrile neutropenic patients with hematological malignancies.

Authors:  Fekade Bruck Sime; Michael S Roberts; Ing Soo Tiong; Julia H Gardner; Sheila Lehman; Sandra L Peake; Uwe Hahn; Morgyn S Warner; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

7.  To Estimate or to Forecast? Lessons From a Comparative Analysis of Four Bayesian Fitting Methods Based on Nonparametric Models.

Authors:  Sylvain Goutelle; Céline Alloux; Laurent Bourguignon; Michael Van Guilder; Michael Neely; Pascal Maire
Journal:  Ther Drug Monit       Date:  2021-08-01       Impact factor: 3.681

Review 8.  Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.

Authors:  Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti
Journal:  Lancet Infect Dis       Date:  2014-04-24       Impact factor: 25.071

9.  DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients?

Authors:  Jason A Roberts; Sanjoy K Paul; Murat Akova; Matteo Bassetti; Jan J De Waele; George Dimopoulos; Kirsi-Maija Kaukonen; Despoina Koulenti; Claude Martin; Philippe Montravers; Jordi Rello; Andrew Rhodes; Therese Starr; Steven C Wallis; Jeffrey Lipman
Journal:  Clin Infect Dis       Date:  2014-01-14       Impact factor: 9.079

10.  Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.

Authors:  V Ramos-Martín; M N Neely; K Padmore; M Peak; M W Beresford; M A Turner; S Paulus; J López-Herce; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

View more
  1 in total

1.  Using Machine Learning To Define the Impact of Beta-Lactam Early and Cumulative Target Attainment on Outcomes in Intensive Care Unit Patients with Hospital-Acquired and Ventilator-Associated Pneumonia.

Authors:  Mohammad H Alshaer; Nicole Maranchick; Chen Bai; Kelly L Maguigan; Bethany Shoulders; Timothy W Felton; Sumith K Mathew; Mamoun T Mardini; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2022-06-14       Impact factor: 5.938

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.